Ad is loading...
MTD
Price
$1179.58
Change
-$58.20 (-4.70%)
Updated
Nov 15 closing price
81 days until earnings call
MYGN
Price
$15.25
Change
-$0.43 (-2.74%)
Updated
Nov 15 closing price
107 days until earnings call
Ad is loading...

MTD vs MYGN

Header iconMTD vs MYGN Comparison
Open Charts MTD vs MYGNBanner chart's image
Mettler-Toledo International
Price$1179.58
Change-$58.20 (-4.70%)
Volume$356.23K
CapitalizationN/A
Myriad Genetics
Price$15.25
Change-$0.43 (-2.74%)
Volume$876.23K
CapitalizationN/A
MTD vs MYGN Comparison Chart
Loading...
MTD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MTD vs. MYGN commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a Sell and MYGN is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (MTD: $1179.58 vs. MYGN: $15.25)
Brand notoriety: MTD and MYGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MTD: 277% vs. MYGN: 108%
Market capitalization -- MTD: $28.69B vs. MYGN: $1.93B
MTD [@Medical Specialties] is valued at $28.69B. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MTD’s FA Score shows that 1 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • MTD’s FA Score: 1 green, 4 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, MTD is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MTD’s TA Score shows that 4 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s).

  • MTD’s TA Score: 4 bullish, 6 bearish.
  • MYGN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, MYGN is a better buy in the short-term than MTD.

Price Growth

MTD (@Medical Specialties) experienced а -9.96% price change this week, while MYGN (@Medical Specialties) price change was -12.41% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.

Reported Earning Dates

MTD is expected to report earnings on Feb 06, 2025.

MYGN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Medical Specialties (-4.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MTD($28.7B) has a higher market cap than MYGN($1.93B). MTD YTD gains are higher at: -2.752 vs. MYGN (-20.324). MTD has higher annual earnings (EBITDA): 1.17B vs. MYGN (-197.4M). MYGN has more cash in the bank: 141M vs. MTD (69.8M). MYGN has less debt than MTD: MYGN (152M) vs MTD (2.08B). MTD has higher revenues than MYGN: MTD (3.79B) vs MYGN (753M).
MTDMYGNMTD / MYGN
Capitalization28.7B1.93B1,489%
EBITDA1.17B-197.4M-594%
Gain YTD-2.752-20.32414%
P/E Ratio37.36N/A-
Revenue3.79B753M503%
Total Cash69.8M141M50%
Total Debt2.08B152M1,369%
FUNDAMENTALS RATINGS
MTD vs MYGN: Fundamental Ratings
MTD
MYGN
OUTLOOK RATING
1..100
850
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
392
PRICE GROWTH RATING
1..100
6493
P/E GROWTH RATING
1..100
441
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MYGN's Valuation (95) in the Biotechnology industry is in the same range as MTD (96) in the Medical Specialties industry. This means that MYGN’s stock grew similarly to MTD’s over the last 12 months.

MTD's Profit vs Risk Rating (47) in the Medical Specialties industry is somewhat better than the same rating for MYGN (100) in the Biotechnology industry. This means that MTD’s stock grew somewhat faster than MYGN’s over the last 12 months.

MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for MYGN (92) in the Biotechnology industry. This means that MTD’s stock grew significantly faster than MYGN’s over the last 12 months.

MTD's Price Growth Rating (64) in the Medical Specialties industry is in the same range as MYGN (93) in the Biotechnology industry. This means that MTD’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for MTD (44) in the Medical Specialties industry. This means that MYGN’s stock grew somewhat faster than MTD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MTDMYGN
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
57%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
65%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
62%
Bullish Trend 19 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 3 days ago
71%
Aroon
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 3 days ago
75%
View a ticker or compare two or three
Ad is loading...
MTD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLDCX18.680.03
+0.16%
Gabelli Gold C
ARGFX79.88-0.60
-0.75%
Ariel Fund Investor
VLAIX46.09-0.44
-0.95%
Value Line Asset Allocation Instl
EXEYX16.53-0.31
-1.84%
Manning & Napier Equity Series S
ABPRX93.18-2.54
-2.65%
AB Large Cap Growth R

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with GMED. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then GMED could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-2.74%
GMED - MYGN
40%
Loosely correlated
N/A
WAT - MYGN
39%
Loosely correlated
-4.85%
VCYT - MYGN
38%
Loosely correlated
-2.97%
FLGT - MYGN
37%
Loosely correlated
-2.70%
MTD - MYGN
36%
Loosely correlated
-4.70%
More